DK2680694T3 - Histondeacetylasehæmmere - Google Patents
Histondeacetylasehæmmere Download PDFInfo
- Publication number
- DK2680694T3 DK2680694T3 DK12751918.9T DK12751918T DK2680694T3 DK 2680694 T3 DK2680694 T3 DK 2680694T3 DK 12751918 T DK12751918 T DK 12751918T DK 2680694 T3 DK2680694 T3 DK 2680694T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- alkyl
- mmol
- pyrazol
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Claims (14)
1. Forbindelse med formlen (I):
hvor: Ar/Het er en 5-leddet heteroaryl valgt fra gruppen bestående af pyrazolyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 3,5-dimethylpyrazolyl og isothiazolyl; X er-Y-[C(Ra)2]a[C(Rb)2]b; hvor: Y er CRc=CRd; a er 1-3; b er 0-3; hver forekomst af Ra og Rb er uafhængigt valgt fra H, F og Cl-C6-alkyl: hver af Rc og Rd er H; hver af R4 og R5 er uafhængigt valgt fra H, Cl-C6-alkyl og F; RI er: (i) C6-C10-aryl, der eventuelt er substitueret med fra 1-3 R°; eller (ii) monocyklisk eller bicyklisk heteroaryl, der indbefatter fra 5-10 ringatomer, der eventuelt er substitueret med fra 1-3 R°; hvor fra 1-4 af ringatomerne et heteroatom er uafhængigt valgt fra O, N, N-H, N-R° og S; eller (iii) heterocyclyl, der indbefatter fra 4-10 ringatomer, der eventuelt er substitueret med fra 1-3 R°; hvor fra 1-4 af ringatomeme et heteroatom er uafhængigt valgt fra O, N, N-H, N-R° og S; hver forekomst af R° uafhængigt er valgt fra gruppen bestående af: • halogen; • Cl-C6-alkyl; fhior(Cl-C6)alkyl; • hydroxyl; • hydroxy(Cl-C4)alkyl; • Cl-C6-alkoxy; fluor(Cl-C6)alkoxy; • (Cl-C6-alkyl)C(O)-; • (Cl-C6-alkyl)NH-; (Cl-C6alkyl)2N-; • formyl; formyl(Cl-C4)alkyl; cyano; cyano(Cl-C4)alkyl;
• SO2-(Cl-C6)alkyl; S0-(Cl-C6)alkyl og • nitro; R2 er H og R3 er H, F eller Cl; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse eller salt ifølge krav 1, hvor hver forekomst af Ra og Rb (når de er til stede) er H.
3. Forbindelse eller salt ifølge et hvilket som helst af de foregående krav, hvor hver af R4 og R5 er H.
4. Forbindelsen eller salt ifølge et hvilket som helst af de foregående krav, hvor R3 er H.
5. Forbindelsen eller salt ifølge et hvilket som helst af kravene 1 til 3, hvor R3 er F eller Cl.
6. Forbindelse eller salt ifølge et hvilket som helst af de foregående krav, hvor Ar/Het er valgt fra pyrazolyl og imidazolyl.
7. Forbindelse eller salt ifølge krav 6, hvor Ar/Het er pyrazolyl.
8. Forbindelse eller salt ifølge et hvilket som helst af de foregående krav, hvor X er -CH=CH-CH2- eller -CH=CHCH2CH2.
9. Forbindelse eller salt ifølge et hvilket som helst af de foregående krav, hvor RI er phenyl, der eventuelt er substitueret med fra 1-3 R°.
10. Forbindelse eller salt ifølge krav 1, der har en struktur valgt fra
11. Farmaceutisk sammensætning, der omfatter en forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1 til 10 og en farmaceutisk acceptabel bærer.
12. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1 til 10, til anvendelse i medicin.
13. Forbindelse, eller et farmaceutisk acceptabelt salt deraf, ifølge et hvilket som helst af kravene 1 til 10, til anvendelse i behandling af en neurologisk forstyrrelse, såsom Friedreichs ataksi, myotonisk dystrofi, spinal muskelatrofi, fragilt X-syndrom, Huntingtons sygdom, spinocerebellar ataksi, Kennedys sygdom, amyotrofisk lateral sklerose, spinal og bulbær muskelatrofi og Alzheimers sygdom; en cancer; en inflammatorisk sygdom; en tilstand med svækket hukommelse eller lægemiddelafhængighed.
14. Forbindelse ifølge krav 13, hvor forstyrrelsen er Friedreichs ataksi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161447416P | 2011-02-28 | 2011-02-28 | |
PCT/US2012/026874 WO2012118782A1 (en) | 2011-02-28 | 2012-02-28 | Histone deacetylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2680694T3 true DK2680694T3 (da) | 2019-03-25 |
Family
ID=46758274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12751918.9T DK2680694T3 (da) | 2011-02-28 | 2012-02-28 | Histondeacetylasehæmmere |
Country Status (9)
Country | Link |
---|---|
US (1) | US9540395B2 (da) |
EP (2) | EP2680694B1 (da) |
JP (3) | JP6250403B2 (da) |
AU (2) | AU2012223509B2 (da) |
CA (2) | CA2828524C (da) |
DK (1) | DK2680694T3 (da) |
ES (1) | ES2712803T3 (da) |
PT (1) | PT2680694T (da) |
WO (1) | WO2012118782A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CA2828524C (en) | 2011-02-28 | 2020-01-07 | Repligen Corporation | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
JP6337255B2 (ja) | 2012-07-27 | 2018-06-06 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | ヒストンデアセチラーゼの阻害剤 |
WO2014100438A1 (en) | 2012-12-20 | 2014-06-26 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
NZ711585A (en) * | 2013-03-15 | 2020-05-29 | Biomarin Pharm Inc | Hdac inhibitors |
WO2015058106A1 (en) * | 2013-10-18 | 2015-04-23 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
WO2016109549A1 (en) | 2014-12-30 | 2016-07-07 | University Of Utah Research Foundation | Hdac1,2 inhibitors and methods of using the same |
US11149062B2 (en) | 2015-08-28 | 2021-10-19 | Uwm Research Foundation, Inc. | HDAC inhibitors and methods of treatment using the same |
CN105920604B (zh) * | 2016-06-08 | 2019-09-03 | 上海荻硕贝肯生物科技有限公司 | 用于治疗白血病的联合用药物及其在治疗白血病中的应用 |
CN106977474B (zh) * | 2017-05-10 | 2020-04-07 | 四川大学 | 一种取代2-氰基-3-苯基呋喃-丙烯酰胺衍生物及其制备方法和用途 |
CN112135610A (zh) * | 2018-01-12 | 2020-12-25 | KDAc治疗股份有限公司 | 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合 |
GB201901559D0 (en) * | 2019-02-05 | 2019-03-27 | Syngenta Crop Protection Ag | Herbicidal compositions |
AR120040A1 (es) | 2019-09-27 | 2022-01-26 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
CN110981868B (zh) * | 2019-11-05 | 2021-08-31 | 中山大学 | 咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途 |
CN113248499A (zh) * | 2021-06-07 | 2021-08-13 | 中国科学院广州生物医药与健康研究院 | 一种吲嗪类化合物的制备及应用 |
WO2023034440A1 (en) | 2021-09-01 | 2023-03-09 | Case Western Reserve University | Treatment of neurodegenerative diseases with hdac inhibitors |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855442A (en) | 1988-04-13 | 1989-08-08 | Monsanto Company | Substituted 3-hydroxy pyrazoles |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6794392B1 (en) | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
JPH11269140A (ja) | 1998-03-23 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
AU2056800A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
EP1182192A4 (en) | 1999-04-09 | 2002-06-05 | Mochida Pharm Co Ltd | 4-HYDROXYPIPERIDINE DERIVATIVES WITH ANTI-ARRHYTHMIC EFFECT |
EP1233958B1 (en) * | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
WO2002018335A1 (fr) | 2000-08-28 | 2002-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amine cyclique |
ATE401395T1 (de) | 2001-05-02 | 2008-08-15 | Univ California | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren |
US20040142859A1 (en) | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
US6784173B2 (en) | 2001-06-15 | 2004-08-31 | Hoffmann-La Roche Inc. | Aromatic dicarboxylic acid derivatives |
AR034897A1 (es) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
CN1578663B (zh) * | 2001-09-14 | 2011-05-25 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
JP2003137866A (ja) | 2001-11-01 | 2003-05-14 | Sankyo Co Ltd | フェニレンジアミン誘導体 |
PL220783B1 (pl) | 2002-03-13 | 2016-01-29 | Janssen Pharmaceutica Nv | Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
US20040072770A1 (en) | 2002-07-03 | 2004-04-15 | Besterman Jeffrey M. | Methods for specifically inhibiting histone deacetylase-7 and 8 |
JP2004035485A (ja) | 2002-07-04 | 2004-02-05 | Mitsui Chemicals Inc | テロメラーゼ阻害剤 |
US20050215601A1 (en) | 2002-09-25 | 2005-09-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient |
CN100448844C (zh) | 2002-10-17 | 2009-01-07 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
CA2503119A1 (en) | 2002-10-25 | 2004-05-13 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
US6852748B1 (en) | 2002-10-30 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide |
TW200426138A (en) | 2002-12-10 | 2004-12-01 | Hoffmann La Roche | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents |
AU2003292888A1 (en) | 2002-12-27 | 2004-07-22 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
PL379553A1 (pl) | 2003-02-10 | 2006-10-16 | Amgen Inc. | Ligandy receptora waniloidowego oraz ich zastosowanie w leczeniu |
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
TW200424187A (en) | 2003-04-04 | 2004-11-16 | Hoffmann La Roche | New oxime derivatives and their use as pharmaceutically active agents |
GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
RU2396250C2 (ru) | 2003-07-24 | 2010-08-10 | Лео Фарма А/С | Новые производные аминобензофенона |
AU2004276337B2 (en) * | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
ES2562778T3 (es) | 2003-12-02 | 2016-03-08 | The Ohio State University Research Foundation | Ácidos grasos de cadena corta unidos a motivos quelantes de Zn2+ como una clase novedosa de inhibidores de histona deacetilasa |
EP1541549A1 (en) | 2003-12-12 | 2005-06-15 | Exonhit Therapeutics S.A. | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods |
EP2272827A1 (en) | 2004-03-11 | 2011-01-12 | 4Sc Ag | Sulphonylpyrroles as hdac inhibitors |
KR101156406B1 (ko) | 2004-03-25 | 2012-06-13 | 아스텔라스세이야쿠 가부시키가이샤 | 솔리페나신 또는 그의 염의 고형 제제용 조성물 |
AU2005225471B2 (en) * | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2008502719A (ja) | 2004-05-21 | 2008-01-31 | メルク エンド カムパニー インコーポレーテッド | アミノシクロペンチル複素環および炭素環系ケモカイン受容体活性調節剤 |
EP1758847A1 (en) | 2004-06-10 | 2007-03-07 | Cancer Research Technology Limited | Inhibitors of histone deacetylase |
WO2006005955A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide derivatives as inhibitors of histone deacetylase |
ATE468853T1 (de) | 2004-07-22 | 2010-06-15 | Merck Sharp & Dohme | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
US8710038B2 (en) | 2004-09-17 | 2014-04-29 | Exelixis, Inc. | Pyrazole kinase modulators and methods of use |
CN101080389A (zh) | 2004-10-15 | 2007-11-28 | 拜尔药品公司 | 具有抗增殖活性的茚满酰胺 |
CN100349070C (zh) | 2004-11-25 | 2007-11-14 | 同济大学 | 一种偶氮/酞菁复合单层有机光电导体及其制备方法 |
CA2590294A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1836199A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases |
EA201100689A1 (ru) | 2005-03-15 | 2011-10-31 | 4Сц Аг | N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
US20060264415A1 (en) | 2005-04-01 | 2006-11-23 | Methylgene Inc. | Inhibitors of histone deacetylase |
EP1868994B1 (en) * | 2005-04-07 | 2011-05-25 | 4Sc Ag | Sulfonylpyrroles as histone deacetylase inhibitors |
US7834034B2 (en) * | 2005-04-20 | 2010-11-16 | Merck Sharp & Dohme Corp. | Benzothiophene derivatives |
US7642253B2 (en) | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP4528918B2 (ja) | 2005-06-21 | 2010-08-25 | 学校法人 関西大学 | カルボキサミド誘導体 |
EP1896395B1 (en) | 2005-06-24 | 2015-07-15 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
EP1904452A2 (en) | 2005-07-14 | 2008-04-02 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CA2620414A1 (en) | 2005-08-26 | 2007-03-01 | Methylgene Inc. | Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase |
KR20080052630A (ko) | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Raf 억제제 화합물 및 그의 사용 방법 |
EP1928872B1 (en) | 2005-09-21 | 2012-03-14 | 4Sc Ag | Novel sulphonylpyrroles as inhibitors of hdac |
NZ566073A (en) | 2005-09-21 | 2011-08-26 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
WO2007044565A2 (en) | 2005-10-06 | 2007-04-19 | University Of Massachusetts | Composition and synthesis of new reagents for inhibition of hiv replication |
GB0521244D0 (en) | 2005-10-19 | 2005-11-30 | Astrazeneca Ab | Benzamide compounds |
US20090105264A1 (en) | 2005-11-03 | 2009-04-23 | Christopher Hamblett | Substituted Nicotinamide Compounds |
US20070219244A1 (en) | 2005-11-11 | 2007-09-20 | The Scripps Research Institute | Histone deacetylase inhibitors as therapeutics for neurological diseases |
AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
WO2007087130A2 (en) | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
AU2007208494A1 (en) | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Fluorinated arylamide derivatives |
JP2009525955A (ja) | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
JP5225104B2 (ja) | 2006-01-19 | 2013-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体 |
AU2007206950B2 (en) | 2006-01-19 | 2012-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
JP5137848B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体 |
CN101374828B (zh) | 2006-01-19 | 2012-09-19 | 詹森药业有限公司 | 作为组蛋白脱乙酰酶抑制剂的杂环烷基衍生物 |
EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
AU2007221207A1 (en) | 2006-02-28 | 2007-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US8598168B2 (en) | 2006-04-07 | 2013-12-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2009537529A (ja) | 2006-05-18 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | アリール縮合スピロ環化合物 |
GB0614070D0 (en) | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
JP2009544611A (ja) | 2006-07-20 | 2009-12-17 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤としてのリン誘導体 |
US8653278B2 (en) | 2006-08-03 | 2014-02-18 | Georgetown University | Isoform selective HDAC inhibitors |
CA2663147A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
CA2662937A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
CA2672192A1 (en) | 2006-12-19 | 2008-06-26 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
US8076332B2 (en) | 2006-12-26 | 2011-12-13 | Santen Pharmaceutical Co., Ltd. | N- (2-aminophenyl) benzamide derivative having urea structure |
WO2008084218A1 (en) | 2007-01-12 | 2008-07-17 | Boehringer Ingelheim International Gmbh | Benzazole derivatives for the treatment of inflammations |
TW200911757A (en) | 2007-01-18 | 2009-03-16 | Takeda San Diego Inc | Crystalline forms of histone deacetylase inhibitors |
US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
NZ598251A (en) | 2007-03-14 | 2013-06-28 | Exelixis Patent Co Llc | 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer |
CN101730703B (zh) | 2007-03-16 | 2012-12-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
CA2680517A1 (en) | 2007-03-28 | 2008-10-02 | Santen Pharmaceutical Co., Ltd. | Novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure |
CA2680838A1 (en) | 2007-03-28 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient |
JP5746860B2 (ja) | 2007-04-09 | 2015-07-08 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
CA2690192A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
JP4567099B2 (ja) | 2007-06-29 | 2010-10-20 | ファイザー・インク | ベンズイミダゾール誘導体 |
US20100267779A1 (en) | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
US20110130361A1 (en) | 2007-08-09 | 2011-06-02 | Jonathan Grimm | Silicon derivatives as histone deacetylase inhibitors |
US20120004222A1 (en) | 2007-08-21 | 2012-01-05 | Zhicai Wu | Cb2 receptor ligands for the treatment of pain |
WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
TW200918521A (en) | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
WO2009033281A1 (en) | 2007-09-14 | 2009-03-19 | Methylgene Inc. | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer |
AU2008300827B2 (en) | 2007-09-19 | 2013-04-04 | 4Sc Ag | Novel tetrahydrofusedpyridines as histone deacetylase inhibitors |
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
NZ584845A (en) | 2007-10-22 | 2011-09-30 | Orchid Res Lab Ltd | Histone deacetylase inhibitors |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
EP2220066A1 (en) | 2007-12-14 | 2010-08-25 | Gilead Colorado, Inc. | Benzofuran anilide histone deacetylase inhibitors |
WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
EP2100882A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts |
AU2009264242A1 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
JP5640006B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | ヒストン脱アセチル化酵素および/またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
JP2011529504A (ja) | 2008-07-28 | 2011-12-08 | ギリアード サイエンシーズ, インコーポレイテッド | シクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物およびヘテロシクロアルキリデンヒストン脱アセチル化酵素阻害剤化合物 |
US9265734B2 (en) | 2008-09-03 | 2016-02-23 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
KR20110055715A (ko) | 2008-09-05 | 2011-05-25 | 엘란 파마슈티칼스, 인크. | N-설폰아미도 폴리사이클릭 피라졸릴 화합물 |
US8202866B2 (en) | 2008-09-17 | 2012-06-19 | Hoffmann-La Roche Inc. | Ortho-aminoanilides for the treatment of cancer |
UY32158A (es) | 2008-10-03 | 2010-04-30 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
US20110212943A1 (en) | 2008-10-15 | 2011-09-01 | Orchid Research Laboratories Limited | Novel bridged cyclic compounds as histone deacetylase inhibitors |
EP2349245B1 (en) | 2008-10-29 | 2016-08-03 | Istituto Superiore di Sanità | Treatment of latent hiv-1 infections using auranofin or arsenic trioxide |
AU2010215524A1 (en) | 2009-02-23 | 2011-06-30 | F. Hoffmann-La Roche Ag | Novel ortho-aminoamides for the treatment of cancer |
KR101145345B1 (ko) | 2009-04-24 | 2012-07-09 | 계명대학교 산학협력단 | 세포증식 억제제로서 유용한 2-싸이오-4-아미노 피리미딘 유도체 및 그 제조방법 |
JP5807971B2 (ja) | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cxcr3受容体アンタゴニスト |
US8362249B2 (en) | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
WO2010127152A2 (en) | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
AU2010259042A1 (en) | 2009-06-08 | 2011-12-15 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물 |
CN101648922B (zh) | 2009-08-20 | 2011-08-31 | 苏州东南药物研发有限责任公司 | 苯甲酰胺类组蛋白去乙酰酶抑制剂及其用途 |
WO2012016081A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Method and therapeutic for the treatment and regulation of memory formation |
CA2828524C (en) | 2011-02-28 | 2020-01-07 | Repligen Corporation | Histone deacetylase inhibitors |
US8957066B2 (en) * | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
-
2012
- 2012-02-28 CA CA2828524A patent/CA2828524C/en not_active Expired - Fee Related
- 2012-02-28 WO PCT/US2012/026874 patent/WO2012118782A1/en active Application Filing
- 2012-02-28 US US13/823,708 patent/US9540395B2/en active Active
- 2012-02-28 EP EP12751918.9A patent/EP2680694B1/en not_active Not-in-force
- 2012-02-28 ES ES12751918T patent/ES2712803T3/es active Active
- 2012-02-28 PT PT12751918T patent/PT2680694T/pt unknown
- 2012-02-28 CA CA3061239A patent/CA3061239A1/en not_active Abandoned
- 2012-02-28 DK DK12751918.9T patent/DK2680694T3/da active
- 2012-02-28 EP EP18214838.7A patent/EP3524324A1/en not_active Withdrawn
- 2012-02-28 JP JP2013556793A patent/JP6250403B2/ja not_active Expired - Fee Related
- 2012-02-28 AU AU2012223509A patent/AU2012223509B2/en not_active Ceased
-
2017
- 2017-02-08 AU AU2017200850A patent/AU2017200850B2/en not_active Ceased
- 2017-08-24 JP JP2017161679A patent/JP2018012718A/ja active Pending
-
2018
- 2018-12-26 JP JP2018242538A patent/JP2019065037A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018012718A (ja) | 2018-01-25 |
CA2828524C (en) | 2020-01-07 |
JP2019065037A (ja) | 2019-04-25 |
JP2014514261A (ja) | 2014-06-19 |
ES2712803T3 (es) | 2019-05-14 |
US9540395B2 (en) | 2017-01-10 |
AU2017200850A1 (en) | 2017-02-23 |
JP6250403B2 (ja) | 2017-12-20 |
EP3524324A1 (en) | 2019-08-14 |
CA3061239A1 (en) | 2012-09-07 |
AU2012223509B2 (en) | 2016-11-10 |
AU2017200850B2 (en) | 2018-09-06 |
WO2012118782A1 (en) | 2012-09-07 |
EP2680694B1 (en) | 2019-01-02 |
CA2828524A1 (en) | 2012-09-07 |
AU2012223509A1 (en) | 2013-09-19 |
US20140051680A1 (en) | 2014-02-20 |
PT2680694T (pt) | 2019-03-14 |
EP2680694A4 (en) | 2014-09-03 |
EP2680694A1 (en) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2680694T3 (da) | Histondeacetylasehæmmere | |
US10301323B2 (en) | Histone deacetylase inhibitors | |
US10981933B2 (en) | Histone deacetylase inhibitors | |
NZ711592B2 (en) | Histone deacetylase inhibitors |